These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 8538038)

  • 1. [Familial bladder cancer].
    Terai A
    Nihon Rinsho; 1995 Nov; 53(11):2749-53. PubMed ID: 8538038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent association of p53 gene mutation in invasive bladder cancer.
    Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
    Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two molecular pathways to transitional cell carcinoma of the bladder.
    Spruck CH; Ohneseit PF; Gonzalez-Zulueta M; Esrig D; Miyao N; Tsai YC; Lerner SP; Schmütte C; Yang AS; Cote R
    Cancer Res; 1994 Feb; 54(3):784-8. PubMed ID: 8306342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of p53 gene mutations in primary human bladder cancer.
    Miyamoto H; Kubota Y; Shuin T; Torigoe S; Hosaka M; Iwasaki Y; Danenberg K; Danenberg PV
    Oncol Res; 1993; 5(6-7):245-9. PubMed ID: 8123944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations and prognosis in bladder tumors.
    Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
    J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
    Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
    Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
    Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
    Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer.
    Hirao S; Hirao T; Marsit CJ; Hirao Y; Schned A; Devi-Ashok T; Nelson HH; Andrew A; Karagas MR; Kelsey KT
    Cancer; 2005 Nov; 104(9):1918-23. PubMed ID: 16149093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
    Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
    Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
    Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
    Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal origin of lymph node metastases in bladder carcinoma.
    Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
    Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
    Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
    J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer.
    Habuchi T; Takahashi R; Yamada H; Ogawa O; Kakehi Y; Ogura K; Hamazaki S; Toguchida J; Ishizaki K; Fujita J
    Cancer Res; 1993 Aug; 53(16):3795-9. PubMed ID: 8339293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
    Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
    Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences.
    Dahse R; Gärtner D; Werner W; Schubert J; Junker K
    Oncol Rep; 2003; 10(6):2033-7. PubMed ID: 14534739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.